Up close and personal: Molecular diagnostics in oncology

Tumor Biology

Volumn 25, Issue 4, 2004, Pages 217-220

  Rye, Phil D ^a   Rittenhouse, Harry ^c   Stigbrand, Torgny ^b  

^a Axis Shield ASA   (Norway)

^b UMEÅ UNIVERSITY   (Sweden)

^c GenProbe   (United States)

Author keywords

Diagnostics; Expression profiling; Microarrays; Molecular oncology; Point of care; Screening; Theranostics

Indexed keywords

ANALYTIC METHOD; CANCER DIAGNOSIS; DIAGNOSTIC PROCEDURE; GENE EXPRESSION; GENOME; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 9244253758     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081105     Document Type: Review

References (34)

1. Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz M: Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications. Washington, AACC Press, 2002.
2. Rye PD, Nustad K, Stigbrand T: Tumor marker workshops. Tumor Biol 2003;24:165-171.
3. Evtimova V, Zeillinger R, Weidle UH: Identification of genes associated with the invasive status of human mammary carcinoma cell lines by transcriptional profiling. Tumor Biol 2003;24:189-198.
4. Schindelmann S, Windisch J, Grundmann R, Kreienberg R, Zeillinger R, Deissler H: Expression profiling of mammary carcinoma cell lines: Correlation of in vitro invasiveness with expression of CD24. Tumor Biol 2002;23:139-145.
5. Li S-R, Ng CFJ, Banerjea A, Ahmed S, Hands R, Powar M, Ogunkolade W, Dorudi S, Bustin SA: Differential expression patterns of the insulin-like growth factor 2 gene in human colorectal cancer. Tumor Biol 2004;25:62-68.
6. Skog S, He Q, Khoshnoud R, Fornander T, Rutqvist L-E: Genes related to growth regulation, DNA repair and apoptosis in an oestrogen receptor-negative (MDA-231) versus an oestrogen receptor-positive (MCF-7) breast tumour cell line. Tumor Biol 2004;25:41-47.
7. Toncheva D, Petrova D, Tzenova V, Dimova I, Yankova R, Yordanov V, Damjanov D, Todorov T, Zaharieva B: Tissue microarray analysis of cyclin D1 gene amplification and gain in colorectal carcinomas. Tumor Biol 2004;25:157-160.
8. Woo IS, Park MJ, Byun JH, Hong YS, Lee KS, Park YS, Lee JA, Park YI, Ahn H-K: Expression of placental growth factor gene in lung cancer. Tumor Biol 2004;25:1-6.
9. Ikeguchi M, Yamaguchi K-I, Kaibara N: Survivin gene expression positively correlates with proliferative activity of cancer cells in esophageal cancer. Tumor Biol 2003;24:40-45.
10. Ikeguchi M, Matsumoto S, Murakami D, Kanaji S, Ohro S, Maeta Y, Tatebe S, Kondo A, Tsujitani S, Kaibara N: Gene expression levels of cytokines in peritoneal washings from patients with gastric cancer. Tumor Biol 2004;25:117-121.
11. Mellick AS, Blackmore D, Weinstein SR, Griffiths LR: An assessment of MMP and TIMP gene expression in cell lines and stroma - tumour differences in microdissected breast cancer biopsies. Tumor Biol 2003;24:258-270.
12. Sasaki H, Yukiue H, Kobayashi Y, Fukai I, Fujii Y: Cten mRNA expression is correlated with tumor progression in thymoma. Tumor Biol 2003;24:271-274.
13. Yang H-J, Liu VWS, Tsang PCK, Yip AMW, Ng T-Y, Cheung ANY, Ngan HYS: Comparison of human papillomavirus DNA levels in gynecological cancers: Implication for cancer development. Tumor Biol 2003;24:310-316.
14. Röijer E, Kosinska U, Andersson I, Nilsson K, Nilsson O: Rearrangement of squamous cell carcinoma antigen genes - detection of SCCA fusion transcripts. Tumor Biol 2003;24:46-52.
15. Hussein MR: The TP53 tumor suppressor gene and melanoma tumorigenesis: Is there a relationship? Tumor Biol 2004;25:200-207.
16. Ueno M, Toyota M, Akino K, Suzuki H, Kusano M, Satoh A, Mita H, Sasaki Y, Nojima M, Yanagihara K, Hinoda Y, Tokino T, Imai K: Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer. Tumor Biol 2004;25:134-140.
17. Ruzzo A, Graziano F, Costagliola A, Arduini F, Testa E, Bearzi I, Cortese G, De Gaetano A, Andreoni F, Lai V, Magnani M: The G/A nucleotide change at cDNA position 2494 in the E-cadherin gene (CDH1): Analysis in Italian patients. Tumor Biol 2003;24:147-150.
18. Siedow A, Szyf M, Gratchev A, Kobalz U, Hanski M-L, Bumke-Vogt C, Foss HD, Riecken EO, Hanski C: De novo expression of the Muc2 gene in pancreas carcinoma cells is triggered by promoter demethylation. Tumor Biol 2002;23:54-60.
19. Naito Y, Takagi T, Handa O, Ishikawa T, Matsumoto N, Yoshida N, Kato H, Ando T, Takemura T, Itani K, Hisatomi H, Tsuchihashi Y, Yoshikawa T: Telomerase activity and expression of telomerase RNA component and catalytic subunits in precancerous and cancerous colorectal lesions. Tumor Biol 2001;22:374-382.
20. Fearon ER: Human cancer syndromes: Clues to the origin and nature of cancer. Science 1997;278:1043-1050.
21. Erichsen HC, Chanock SJ: SNP's in cancer research and treatment. Br J Cancer 2004;90:747-751.
22. Clifford RJ, Edmonson MN, Nguyen C, Scherpbier T, Hu Y, Buetow KH: Bioinformatics tools for single nucleotide polymorphism discovery and analysis. Ann NY Acad Sci 2004;1020:101-109.
23. Schena M, Shalon D, Davis RW, Brown PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995;270:467-470.
24. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA, Trent JM: Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 1996;14:457-460.
25. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang C, Kobayashi M, Horton H, Brown EL: Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996;14:1675-1680.
26. Duggan DJ, Bittner M, Chen Y, Meltzer P, Trent JM: Expression profiling using cDNA microarrays. Nat Genet 1999;21(suppl 1):10-14.
27. Brown PO, Botstein D: Exploring the new world of the genome with DNA microarrays. Nat Genet 1999;21(suppl 1):33-37.
28. Russo G, Zegar C, Giordano A: Advantages and limitations of microarray technology in human cancer. Oncogene 2003;22:6497-6507.
29. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA et al.: DD3: a new prostate-specific gene, highly over expressed in prostate cancer. Cancer Res 1999;59(23):5975-5979.
30. Hessels D, Grunnewiek JMT, van Oort I, Karthaus FM, van Leenders GJL, van Balken B, Kiemeney LA, Witjes JA, Schalken JA: European Urology 2003;44:8-16.
31. Fradet Y, Saad F, Aprikian A, Dessaureault J, Elhilali M, Trudel C, Masse B, Piche L, Chypre C: uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004;64:1-19.
32. Lazarou J, Pomeranz B, Corey PN: Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998;279:1200-1205.
33. Preventable Adverse Drug Reactions: A Focus on Drug Interactions. An online presentation by the CDER at http://www.fda.gov/cder/drug/ drugReactions/default.htm
34. Petty EM, Yashar BM: Molecular genetic diagnosis of inherited cancer predisposition; in Coleman WB, Tsongalis GJ (eds): The Molecular Basis of Human Cancer. Human Press, Totowa, NJ, 2002, pp 497-520.